• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications do not work for many people suffering from depression in elderly treatment. Personalized treatment may be the solution.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into personalised micro-interventions to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to understand their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is among the world's leading causes of mental illness.1 Yet, only half of people suffering from the disorder receive treatment1. To improve outcomes, healthcare professionals must be able to identify and treat patients who are the most likely to respond to specific treatments.

The home treatment for depression of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from certain treatments. They are using sensors on mobile phones, a voice assistant with artificial intelligence and other digital tools. With two grants totaling more than $10 million, they will employ these techniques to determine biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research to so far has focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education and clinical characteristics like severity of symptom and comorbidities as well as biological markers.

While many of these factors can be predicted from the data in medical records, very few studies have used longitudinal data to determine the factors that influence mood in people. Many studies do not take into consideration the fact that mood can be very different between individuals. Therefore, it is crucial to develop methods that permit the determination of individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can detect different patterns of behavior and emotion that are different between people.

In addition to these methods, the team also developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm combines the individual characteristics to create a unique "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of Symptoms

depression Treatment history is among the leading causes of disability1, but it is often untreated and not diagnosed. In addition an absence of effective interventions and stigma associated with depressive disorders prevent many individuals from seeking help.

To allow for individualized treatment in order to provide a more personalized homeopathic treatment for depression, identifying factors that predict the severity of symptoms is crucial. The current methods for predicting symptoms rely heavily on clinical interviews, which are not reliable and only detect a few symptoms associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements as well as capture a variety of distinct behaviors and patterns that are difficult to record with interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical care according to the severity of their depression. Those with a score on the CAT DI of 35 or 65 were assigned to online support with the help of a peer coach. those who scored 75 were sent to clinics in-person for psychotherapy.

At the beginning, participants answered an array of questions regarding their personal characteristics and psychosocial traits. These included age, sex, education, work, and financial status; whether they were divorced, partnered, or single; current suicidal thoughts, intentions or attempts; and the frequency with which they drank alcohol. Participants also rated their level of depression treatment centers near me symptom severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted each week for those who received online support and weekly for those receiving in-person care.

Predictors of the Reaction to Treatment

The development of a personalized depression treatment is currently a top research topic and many studies aim at identifying predictors that will enable clinicians to determine the most effective medication for each person. Pharmacogenetics in particular identifies genetic variations that determine the way that our bodies process drugs. This enables doctors to choose drugs that are likely to be most effective for each patient, reducing the time and effort in trials and errors, while eliminating any side effects that could otherwise slow advancement.

Another promising method is to construct prediction models using multiple data sources, combining clinical information and neural imaging data. These models can be used to identify which variables are most predictive of a particular outcome, such as whether a medication will improve symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness of their treatment.

A new generation uses machine learning techniques like algorithms for classification and supervised learning, regularized logistic regression and tree-based methods to integrate the effects of multiple variables to improve the accuracy of predictive. These models have shown to be effective in predicting treatment outcomes such as the response to antidepressants. These methods are becoming more popular in psychiatry and could be the norm in future medical practice.

In addition to ML-based prediction models, research into the mechanisms that cause depression continues. Recent research suggests that the disorder is associated with neurodegeneration in particular circuits. This theory suggests that the treatment for depression treatment centers will be individualized built around targeted therapies that target these circuits to restore normal functioning.

Internet-based interventions are an option to accomplish this. They can offer more customized and personalized experience for patients. One study discovered that a web-based treatment was more effective than standard care in improving symptoms and providing an improved quality of life for those with MDD. A controlled study that was randomized to an individualized treatment for depression revealed that a significant number of patients saw improvement over time and had fewer adverse effects.

Predictors of adverse effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients are prescribed various drugs before they find a drug that is effective and tolerated. Pharmacogenetics offers a fresh and exciting way to select antidepressant medications that is more efficient and targeted.

There are several variables that can be used to determine the antidepressant to be prescribed, such as gene variations, patient phenotypes such as gender or ethnicity and co-morbidities. However, identifying the most reliable and accurate predictors for a particular treatment will probably require randomized controlled trials of significantly larger numbers of participants than those typically enrolled in clinical trials. This is because it could be more difficult to identify moderators or interactions in trials that contain only one episode per person rather than multiple episodes over time.

In addition, predicting a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's subjective perception of the effectiveness and tolerability. At present, only a handful of easily assessable sociodemographic variables and clinical variables seem to be reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics for depression treatment. First, a clear understanding of the underlying genetic mechanisms is required and an understanding of what constitutes a reliable predictor for treatment response. In addition, ethical issues like privacy and the responsible use of personal genetic information, should be considered with care. Pharmacogenetics can, in the long run reduce stigma associated with mental health treatments and improve the quality of treatment. However, as with any approach to psychiatry careful consideration and planning is necessary. At present, it's best to offer patients an array of depression medications that are effective and encourage them to speak openly with their doctors.